日本全国新心力衰竭药物处方调查由儿童心脏病学家进行
Jun Muneuchi1,2,
1Department of Pediatrics, Kyushu Hospital Kitakyushu Japan.
Circulation reports
|March 11, 2026
概括
日本儿童心脏病专家越来越多地开出新的心力衰竭药物,如SGLT-2i和ARNI. 进一步的儿科专用试验和指导方针对于儿童的安全和有效使用至关重要.
科学领域:
- 心脏病学 心脏病学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- 调查了日本儿科心脏病学中新型心力衰竭药物处方的当前情况.
- 突出了对儿科心脏病的先进药物治疗方法的日益使用.
研究的目的:
- 在日本儿科心脏病专家中调查新的心力衰竭药物的处方模式.
- 了解SGLT-2i,ARNI,HCN阻断剂和sGC刺激剂在儿科护理中的初始吸收和患者群.
主要方法:
- 全国97个日本儿科心脏病机构的调查.
- 对接受新型药物治疗的357名儿科心力衰竭患者的处方数据的分析.
主要成果:
- -葡萄糖携带载体-2 抑制剂 (SGLT-2i) 处方给 189 名患者,主要是后方顿病例 (45%) 和三分之一的 18 岁以下患者.
- ангиотензин受体-neprilysin抑制剂 (ARNI) 在89名患者中使用,经常用于双心室先天性心脏病 (47%) 和心肌病 (29%),其中40%的受体年龄在18岁以下.
- 选择性高极化激活周期性核酸通道 (HCN) 阻断剂被开给了76名患者,可溶性酸环酶 (sGC) 刺激剂被开给了3名患者.
结论:
- 迫切需要为新的心力衰竭药物进行儿科专用临床试验.
- 开发基于证据的使用指南对于优化儿科心力衰竭治疗至关重要.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
605
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
411
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411